deltatrials
Completed PHASE1/PHASE2 INTERVENTIONAL 1-arm NCT01212952

Pomalidomide, Bortezomib, and Dexamethasone in Treating Patients With Relapsed or Refractory Multiple Myeloma

MC1082: A Phase I/II Trial of Pomalidomide (CC-4047), Bortezomib, and Dexamethasone in Patients With Relapsed or Refractory Multiple Myeloma

Sponsor: Mayo Clinic

Conditions Refractory Multiple Myeloma
Interventions bortezomib dexamethasone gene expression analysis laboratory biomarker analysis pomalidomide
Updated 12 times since 2017 Last updated: Apr 7, 2020 Started: Sep 30, 2011 Primary completion: Aug 15, 2017 Completion: Mar 22, 2018
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A PHASE1/PHASE2 clinical study on Refractory Multiple Myeloma, this trial is completed. The trial is conducted by Mayo Clinic and has accumulated 12 data snapshots since 2011. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.

Status Flow

~Jan 2017 – ~Feb 2017 · 31 days · monthly snapshotActive Not Recruiting~Feb 2017 – ~Apr 2017 · 59 days · monthly snapshotActive Not Recruiting~Apr 2017 – ~Apr 2018 · 12 months · monthly snapshotActive Not Recruiting~Apr 2018 – ~Jun 2018 · 2 months · monthly snapshotCompleted~Jun 2018 – ~Mar 2019 · 9 months · monthly snapshotCompleted~Mar 2019 – ~May 2020 · 14 months · monthly snapshotCompleted~May 2020 – ~Jan 2021 · 8 months · monthly snapshotCompleted~Jan 2021 – ~Dec 2022 · 23 months · monthly snapshotCompleted~Dec 2022 – ~Jan 2023 · 31 days · monthly snapshotCompleted~Jan 2023 – ~Jul 2024 · 18 months · monthly snapshotCompleted~Jul 2024 – ~Sep 2024 · 2 months · monthly snapshotCompleted~Sep 2024 – present · 24 months · monthly snapshotCompleted

Change History

12 versions recorded

  1. Sep 2024 — Present [monthly]

    Completed PHASE1/PHASE2

  2. Jul 2024 — Sep 2024 [monthly]

    Completed PHASE1/PHASE2

    Phase: PHASE1_PHASE2 → PHASE1/PHASE2

  3. Jan 2023 — Jul 2024 [monthly]

    Completed PHASE1_PHASE2

  4. Dec 2022 — Jan 2023 [monthly]

    Completed PHASE1_PHASE2

  5. Jan 2021 — Dec 2022 [monthly]

    Completed PHASE1_PHASE2

▶ Show 7 earlier versions

  1. May 2020 — Jan 2021 [monthly]

    Completed PHASE1_PHASE2

  2. Mar 2019 — May 2020 [monthly]

    Completed PHASE1_PHASE2

  3. Jun 2018 — Mar 2019 [monthly]

    Completed PHASE1_PHASE2

  4. Apr 2018 — Jun 2018 [monthly]

    Completed PHASE1_PHASE2

    Status: Active Not Recruiting → Completed

  5. Apr 2017 — Apr 2018 [monthly]

    Active Not Recruiting PHASE1_PHASE2

  6. Feb 2017 — Apr 2017 [monthly]

    Active Not Recruiting PHASE1_PHASE2

  7. Jan 2017 — Feb 2017 [monthly]

    Active Not Recruiting PHASE1_PHASE2

    First recorded

Sep 2011

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • Mayo Clinic
  • National Cancer Institute (NCI)
Data source: Mayo Clinic

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations